Value of Cantrixil, page-7

12:00 - 12:00 1034P - Phase I Study of Intraperitoneal TRX-E-002-1 in Subjects with Persistent
or Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer: Three-month
Follow-up Results of the Dose Escalation Phase
J. Coward1, G. Kichenadasse2, P. Harnett3, K. Moore4, M. Barve5, D. Berg6, J. Garner6, D.
Dizon7, 1Icon Cancer Centre, South Brisbane, AU, 2Flinders Medical Centre, Adelaide,
AU, 3Westmead Hospital, Westmead, AU, 4Stephenson Cancer Center at the University of
Oklahoma, Oklahoma City, US, 5Mary Crowley Cancer Center, Dallas, US, 6Kazia
Therapeutics Limited, Sydney, AU, 7Lifespan Cancer Institute, Rhode Island, US